Eli Lilly Faces Criticism Over Mounjaro Price Increase Plans
Challenges in Accessing Mounjaro Due to Price Surge
Patients in the UK are encountering significant difficulties in acquiring Mounjaro, a medication known for weight management and diabetes control, as demand escalates ahead of an imminent price hike. Eli Lilly and Co, the American company behind this medication, has announced a staggering increase in Mounjaro's price, raising it by as much as 170%. This price surge will affect the highest dosage, with costs escalating from £122 to £330 monthly.
Patient Concerns Over 'Stressful' Shortages
Individuals dependent on Mounjaro for their health have expressed their frustrations regarding the shortages. Lynne Massey-Davis, a 65-year-old from East Yorkshire, described the ongoing situation as "stressful." After experiencing a delay with her prescription, she resorted to paying £349 to a different supplier, who ultimately reported being out of stock. "I am left in a holding queue," she explained. "This period feels incredibly uncertain, and I have spent countless hours trying to resolve this situation on the phone."
NHS Patients Worried About Losing Their Progress
Marie Cook, a 49-year-old from east London, voiced similar concerns. Having used Mounjaro through the NHS for her type 2 diabetes, she noted her impressive progress, including a loss of 3.5 stones and discontinuing insulin. However, she is now down to just one week’s supply of injections, which adds to her frustration. "We face real medical challenges, and prioritizing our needs should be essential," she asserted.
National Pharmacy Association's Call for Caution
The National Pharmacy Association acknowledged the strain on supply chains due to this impending price hike. Chief executive Henry Gregg urged patients to be cautious, especially against unlicensed online providers. "This situation can significantly affect the availability of the drug and may lead to safety risks for patients," he warned.
Recent Initiatives to Improve Access to Weight Management
In response to rising concerns over obesity-related health issues, the UK government recently announced a new initiative aimed at expanding access to weight management services. Collaborating with Eli Lilly, the program seeks to provide support through community-based approaches, pharmacies, and digital platforms, benefiting those struggling with obesity.
This initiative is being backed by approximately £85 million ($114.61 million), highlighting the government's commitment to tackling obesity and its related health challenges. Eli Lilly will contribute up to £35 million in grant funding.
Emerging Developments in Weight-Loss Medication
During the developments surrounding Mounjaro, Eli Lilly also provided updates on its latest weight-loss drug, Orforglipron. In the Phase 3 ATTAIN-1 trial, the medication demonstrated an average weight loss of 12.4% (27.3 lbs) at a 36 mg dose, albeit falling short of the anticipated 15% threshold from Wall Street expectations.
Potential Changes in Medicare Access to Weight-Loss Drugs
Simultaneously, plans have emerged indicating that the upcoming US administration may introduce a pilot program allowing Medicare and Medicaid participants voluntary access to costly weight-loss drugs, which includes Mounjaro among others. This potential shift could substantially influence how patients access these vital medications moving forward.
Price Action for Eli Lilly Shares
In terms of stock market performance, Eli Lilly shares experienced a slight decline of 0.25%, priced at $734.17 during regular trading hours. However, a marginal recovery of 0.65% was noted in pre-market activity.
Frequently Asked Questions
What led to the spike in Mounjaro's price?
Eli Lilly announced a 170% price increase to cover costs and reflect market demand, significantly impacting patient access.
How are patients reacting to Mounjaro shortages?
Patients have expressed feelings of stress and frustration, as they struggle to secure their medications amidst rising demand and limited stocks.
What is the NHS doing regarding weight management services?
The NHS has initiated a program aimed at improving access to weight management services, funded collaboratively with Eli Lilly, to support patients in need.
How does Orforglipron compare to Mounjaro?
Orforglipron recently showed a 12.4% weight loss in trials, while Mounjaro has been effective for many patients managing diabetes and weight issues.
What should patients do if they cannot access Mounjaro?
Patients are advised to contact their healthcare providers for advice and to avoid unlicensed online sellers to ensure safety in obtaining necessary medications.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.